Kinase inhibitor specialist Kinnate launches Shanghai subsidiary with $35M to market its programs in China
A little more than five months after going public with a $276 million IPO, Kinnate Biopharma is back raising money — this time for a new subsidiary launching in China.
The yet-to-be named company is launching Thursday with a $35 million Series A round, Kinnate said, and it will be a joint venture with some of Kinnate’s previous investors. OrbiMed Asia Partners, OrbiMed Private Investments and Foresite Capital are all helping establish the company, with Kinnate taking the role as majority stakeholder.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.